Insider filing · REPL
Philip Astley-Sparke
Director
profile →
Replimune Group, Inc.
REPL · Healthcare · 10 filings in 24 months
ticker →
Philip Astley-Sparke sold $260K of Replimune (REPL)
Executed May 20 2025, disclosed May 22 2025, 2 days later.
Value, as filed
$260K
32,279 sh × $8.06
Executed
May 20 2025
the trade date, as filed
Disclosed
May 22 2025
2 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
PSPhilip Astley-Sparke (Director) filed 1 Form 4 report in the past 24 months (0 purchases, 1 sale), most often in Replimune Group, Inc. (REPL). The largest single filing was $260K of REPL (32,279 sh × $8.06, as filed), executed May 20 2025.
The name
REPLHealthcare · Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapie…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→